Lilly's Olumiant Makes Big Leap In Lupus Trial
Executive Summary
A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis (RA), Lilly has some strong Phase II data banked for its JAK inhibitor in lupus.
You may also be interested in...
Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos
Impressive Phase II data for Gilead and Galapagos’ filgotinib in psoriatic arthritis and progress into Phase III for ulcerative colitis suggest that the investigational JAK inhibitor could potentially become a market leader in the class for these and other inflammatory indications.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.